Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Disease Progression × Bortezomib × Clear all

Phase

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 212 Neoplasms, Plasma Cell 45 Lymphoma 37 Lymphoma, Mantle-Cell 35 Lymphoma, Non-Hodgkin 25 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Recurrence 23 Leukemia, Myeloid, Acute 22 Waldenstrom Macroglobulinemia 21 Lymphoma, Large B-Cell, Diffuse 19 Lymphoma, Follicular 18 Leukemia 18 Lymphoma, B-Cell, Marginal Zone 17 Immunoglobulin Light-chain Amyloidosis 17 Carcinoma, Non-Small-Cell Lung 12 Neoplasms 11 Leukemia, Lymphocytic, Chronic, B-Cell 11 Myelodysplastic Syndromes 10 Breast Neoplasms 10 Lymphoma, T-Cell, Peripheral 9 Hodgkin Disease 9 Hematologic Neoplasms 9 Prostatic Neoplasms 8 Lung Neoplasms 8 Burkitt Lymphoma 8 Renal Insufficiency 7 Lymphoma, Large-Cell, Anaplastic 7 Lymphoma, B-Cell 7 Immunoblastic Lymphadenopathy 7 Pancreatic Neoplasms 6

Interventions

pembrolizumab 2 fludarabine 2 Radiosurgery 2 Paclitaxel 2 Cyclophosphamide 2 Cisplatin 2 Carboplatin 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 pazopanib 1 niraparib 1 lutetium Lu 177 dotatate 1 ibrutinib 1 grapiprant 1 fludarabine phosphate 1 famitinib 1 encorafenib 1 copanlisib 1 cemiplimab 1 capivasertib 1 camrelizumab 1 brigatinib 1 binimetinib 1 axicabtagene ciloleucel 1 avasopasem manganese 1 abexinostat 1 Transplantation, Autologous 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01191060 2019-04-18

IFM/DFCI2009

University Hospital, Toulouse

Phase 3 Completed

Disease Progression, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡